WO2000018353A3 - Nouvel inhibiteur de formation de cataracte - Google Patents

Nouvel inhibiteur de formation de cataracte Download PDF

Info

Publication number
WO2000018353A3
WO2000018353A3 PCT/US1999/022354 US9922354W WO0018353A3 WO 2000018353 A3 WO2000018353 A3 WO 2000018353A3 US 9922354 W US9922354 W US 9922354W WO 0018353 A3 WO0018353 A3 WO 0018353A3
Authority
WO
WIPO (PCT)
Prior art keywords
cataract formation
novel inhibitor
mammal
methods
tetracycline derivative
Prior art date
Application number
PCT/US1999/022354
Other languages
English (en)
Other versions
WO2000018353A2 (fr
Inventor
Maria Emanuel Ryan
Lorne M Golub
Nungavaram S Ramamurthy
Original Assignee
Univ New York State Res Found
Maria Emanuel Ryan
Lorne M Golub
Nungavaram S Ramamurthy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found, Maria Emanuel Ryan, Lorne M Golub, Nungavaram S Ramamurthy filed Critical Univ New York State Res Found
Priority to US09/787,866 priority Critical patent/US6914057B1/en
Priority to CA002343038A priority patent/CA2343038A1/fr
Priority to EP99949910A priority patent/EP1124558A4/fr
Priority to KR1020017003876A priority patent/KR20010073190A/ko
Priority to JP2000571875A priority patent/JP2002525299A/ja
Priority to NZ510628A priority patent/NZ510628A/en
Priority to AU62684/99A priority patent/AU759372B2/en
Publication of WO2000018353A2 publication Critical patent/WO2000018353A2/fr
Publication of WO2000018353A3 publication Critical patent/WO2000018353A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des méthodes de réduction du risque de cataracte chez un mammalien, les méthodes consistant à administrer au mammalien une quantité effective d'un dérivé de tétracycline. De préférence, un dérivé de tétracycline administré selon les méthodes de la présente invention consiste en 6α-désoxy 5-hydroxy-4-dédiméthylaminotétracycline.
PCT/US1999/022354 1998-09-28 1999-09-28 Nouvel inhibiteur de formation de cataracte WO2000018353A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US09/787,866 US6914057B1 (en) 1998-09-28 1999-09-28 Inhibitor of cataract formation
CA002343038A CA2343038A1 (fr) 1998-09-28 1999-09-28 Nouvel inhibiteur de formation de cataracte
EP99949910A EP1124558A4 (fr) 1998-09-28 1999-09-28 Nouvel inhibiteur de formation de cataracte
KR1020017003876A KR20010073190A (ko) 1998-09-28 1999-09-28 백내장 형성 억제제
JP2000571875A JP2002525299A (ja) 1998-09-28 1999-09-28 新規白内障形成抑制剤
NZ510628A NZ510628A (en) 1998-09-28 1999-09-28 Use of a tetracycline derivative for reducing the risk of cataract formation in a mammal
AU62684/99A AU759372B2 (en) 1998-09-28 1999-09-28 A novel inhibitor of cataract formation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10205698P 1998-09-28 1998-09-28
US60/102,056 1998-09-28

Publications (2)

Publication Number Publication Date
WO2000018353A2 WO2000018353A2 (fr) 2000-04-06
WO2000018353A3 true WO2000018353A3 (fr) 2000-07-06

Family

ID=22287890

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/022354 WO2000018353A2 (fr) 1998-09-28 1999-09-28 Nouvel inhibiteur de formation de cataracte

Country Status (7)

Country Link
EP (1) EP1124558A4 (fr)
JP (1) JP2002525299A (fr)
KR (1) KR20010073190A (fr)
AU (1) AU759372B2 (fr)
CA (1) CA2343038A1 (fr)
NZ (1) NZ510628A (fr)
WO (1) WO2000018353A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506740B1 (en) 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
AU766200B2 (en) * 1998-11-18 2003-10-09 Collagenex Pharmaceuticals, Inc. Novel 4-dedimethy laminotetra cycline derivatives
KR100982753B1 (ko) * 2001-04-05 2010-09-16 콜라제넥스 파마슈티칼스, 인크 테트라사이클린 화합물 및 테트라사이클린 유도체의 전달조절
PT1383508E (pt) * 2001-04-05 2006-11-30 Collagenex Pharm Inc Doxiciclina destinada ao tratamento da acne
EP2311798A1 (fr) * 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. Composés de tétracycline 4-dedimethylamino
US7749532B2 (en) 2003-04-07 2010-07-06 Supernus Pharmaceuticals, Inc. Once daily formulations of tetracyclines
ES2558512T3 (es) 2008-08-08 2016-02-04 Tetraphase Pharmaceuticals, Inc. Compuestos de tetraciclina sustituida con C7-fluoro
CN102459153A (zh) 2009-05-08 2012-05-16 四相制药公司 四环素类化合物
CN105622496B (zh) 2009-08-28 2019-03-05 四相制药公司 四环素类化合物
PT2890673T (pt) 2012-08-31 2019-02-19 Tetraphase Pharmaceuticals Inc Compostos de tetraciclina
US10961190B2 (en) 2016-10-19 2021-03-30 Tetraphase Pharmaceuticals, Inc. Crystalline forms of eravacycline

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244673A (en) * 1989-09-29 1993-09-14 Institute Of Macromolecular Chemistry Of The Academy Of Sciences Of The Czech Republic Medicamentous form for use as an ophthalmologic, otolaryngologic, or dermatologic drug
US5474764A (en) * 1993-02-08 1995-12-12 Insite Vision Incorporated Alkaline ophthalmic suspensions
US5814655A (en) * 1996-11-14 1998-09-29 Insite Vision Incorporated Non-steroidal ophthalmic mixtures
US5929055A (en) * 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0515954A (ja) * 1991-07-10 1993-01-26 Harima Ceramic Co Ltd ポーラス質スライデイングノズルプレート
JPH09315954A (ja) * 1996-05-30 1997-12-09 Kita:Kk 眼科手術後の眼組織混濁防止剤。

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244673A (en) * 1989-09-29 1993-09-14 Institute Of Macromolecular Chemistry Of The Academy Of Sciences Of The Czech Republic Medicamentous form for use as an ophthalmologic, otolaryngologic, or dermatologic drug
US5474764A (en) * 1993-02-08 1995-12-12 Insite Vision Incorporated Alkaline ophthalmic suspensions
US5814655A (en) * 1996-11-14 1998-09-29 Insite Vision Incorporated Non-steroidal ophthalmic mixtures
US5929055A (en) * 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1124558A4 *

Also Published As

Publication number Publication date
AU759372B2 (en) 2003-04-10
WO2000018353A2 (fr) 2000-04-06
EP1124558A2 (fr) 2001-08-22
KR20010073190A (ko) 2001-07-31
CA2343038A1 (fr) 2000-04-06
NZ510628A (en) 2003-08-29
EP1124558A4 (fr) 2004-10-27
AU6268499A (en) 2000-04-17
JP2002525299A (ja) 2002-08-13

Similar Documents

Publication Publication Date Title
CA2289717A1 (fr) Nouveau traitement de la constipation
AU2122995A (en) Inhibition of cataracts and other disorders
LU91346I2 (fr) Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige)
PL335421A1 (en) Method of preventing and retarding occurence of alzheimer diseases as well as preparation therefor
LU91655I2 (fr) Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®)
ZA964735B (en) Compositions and methods for topical administration of pharmaceutically active agents
LU91624I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
EP1268412B8 (fr) D riv s de bicyxloalkyle pontage substitution sulphonamido
AU5493598A (en) N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
WO1999005096A3 (fr) Inhibiteurs d'urokinase
AU6851696A (en) Compositions containing hydroperoxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
AU8140898A (en) Inhibitors of beta-lactamases and uses therefor
AU6094996A (en) Diphosphonate derivatives of therapeutic agents
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
AU3922193A (en) Liposome encapsulated taxol and a method of using the same
AU1709699A (en) 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
AU5729596A (en) Localized use of nitric oxideadducts to prevent internal tis sue damage
AU7578696A (en) Morpholine derivatives and their use as therapeutic agents
EE04091B1 (et) Koostised ja meetodid silmasisese rõhu alandamiseks
AU1041599A (en) Therapeutic uses of triazolo-pyridazine derivatives
WO2003020202A3 (fr) Methode permettant de reduire l'hypertension et l'insuffisance cardiaque
WO2000018353A3 (fr) Nouvel inhibiteur de formation de cataracte
EP1167354A3 (fr) Huperzine A racémique
AU2626895A (en) Production and uses of caffeic acid and derivatives thereof
AU8038998A (en) Prophylactic or therapeutic agent for diseases attributable to infection with helicobacters

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2343038

Country of ref document: CA

Ref country code: CA

Ref document number: 2343038

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 62684/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 510628

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 09787866

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020017003876

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 571875

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999949910

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017003876

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999949910

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 62684/99

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020017003876

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999949910

Country of ref document: EP